Back Bay Grows International Leadership in Diagnostic Development, Clinical and Regulatory Affairs
Back Bay Life Science Advisors, a global life science strategy and investment banking partnership, announced the expansion of their senior advisory board with Donna J. Edmonds and Rick Sax, MD.
With this expansion, the Back Bay team adds further expertise in diagnostic development, clinical and regulatory support for global biopharma, medtech and diagnostics development. Berthold Hackl joined the board in April as senior advisor based in Europe, collaborating with our portfolio of European biopharma, medtech and diagnostic clients.
Diagnostics Development
The addition of Donna. J. Edmonds further enhances Back Bay’s expertise and reach in diagnostics. Ms. Edmonds is CEO of Brainbox Solutions and a recognized leader in diagnostics development. She has held senior management and leadership roles in ten diagnostic companies.
Ms. Edmonds brings to Back Bay’s advisory board more than 30 years of experience in healthcare, beginning as a critical care nurse, and migrating to operating and senior management in hospital, physician group practices, and then diagnostic industry positions.
Ms. Edmonds is recognized for leading change in the clinical practice of cardiovascular diagnostics, including the practice-changing development of the first two Troponin (including point of care) assays, as well as a broad portfolio of cardiac biomarkers. She formed Virginia Life Sciences Investments, Inc. and led Series A investment in ImmunArray, the original home of a broad portfolio of biomarkers for neurological disease diagnosis and monitoring.
Ms. Edmonds further enhances Back Bay’s strong presence in the advancement and delivery of medtech and diagnostic tools. She adds corporate leadership experience in the team’s cardiovascular and neurology therapeutic area expertise.
Clinical and Regulatory Execution
Rick Sax, MD, brings further expert clinical and regulatory guidance to the Back Bay team. He is managing director of Pharma Design Solutions, a UK-based drug development advisory. Dr. Sax is a senior leader in the pharmaceutical industry and offers valued perspectives on global clinical and regulatory affairs. In addition, he is a founding leader of IQVIA’s Cell and Gene Therapy group, dovetailing with Back Bay’s unparalleled expertise in gene therapy innovation.
Dr. Sax has held senior positions in clinical development at Merck & Co, AstraZeneca, and Quintiles where he oversaw biostatistics, medical writing, and global clinical and regulatory affairs, among other areas.
The senior advisory board provides extended, seasoned expertise and guidance to Back Bay’s portfolio of international biopharma and medtech clients and partners.
About Back Bay Life Science Advisors
Back Bay Life Science Advisors is recognized worldwide as a reliable, expert partner for every stage of life science and medtech development. Back Bay is the only Boston-based global advisory providing seasoned strategic guidance integrated with investment banking expertise. From startup through M&A and beyond, Back Bay is a partner for every stage and sector. Learn more about our international expertise at www.bblsa.com.